Resolver launches pharma risk monitoring service for the wider web

By AI, Created 5:20 PM UTC, May 18, 2026, /AGP/ – Resolver has introduced a fully managed online risk intelligence service for pharmaceutical brands that expands monitoring beyond owned and paid social channels to Reddit, patient forums and other digital communities. The offering is designed to give communications, marketing and pharmacovigilance teams earlier visibility into misinformation, supply chain, pricing and adverse event signals while supporting FDA and EMA compliance.

Why it matters: - Pharmaceutical brands can now monitor risk across the wider web without building and managing their own compliance process. - The service is aimed at earlier detection of brand, reputational and safety issues that can spread outside owned channels. - Resolver says the offering helps teams meet FDA and EMA compliance expectations while reducing visibility gaps.

What happened: - Resolver launched Risk Monitoring for Pharmaceutical Brands, a managed online risk intelligence service for pharma teams. - The service extends monitoring beyond owned and paid social channels to the wider web, including Reddit, patient forums and niche digital communities. - Resolver says the service is the industry’s first fully managed solution of its kind. - The launch was announced May 12, 2026, in Toronto.

The details: - The service gives communications, marketing and pharmacovigilance teams 24/7, 365-day coverage. - Resolver says the system includes a 100% adverse event detection guarantee. - Monitored risk signals include misinformation, supply chain issues, pricing issues and adverse event signals. - Resolver says internal teams cannot safely monitor these channels at scale. - Communications teams receive verified and contextualized intelligence reports they can act on. - When adverse event signals are detected, Resolver’s pharmacovigilance-trained analysts triple-check and validate each one before it enters a documented compliance workflow. - The service gives cross-functional teams a shared view without requiring them to manage the monitoring process separately. - Resolver says the offering builds on more than 15 years of experience supporting regulated industries with AI-supported detection and expert human analysis. - The service also covers ESG, product and safety initiatives through a unified reputation view. - It is designed to detect generative AI misinformation and coordinated brand attacks by assessing intent and context across global conversations. - The reporting is intended to explain what is driving narrative shifts so leadership can make decisions with more confidence. - Organizations can request a Pharma Risk Briefing with a Resolver industry-trained analyst. - The briefing is meant to help teams understand how digital risk is developing across channels, products and the broader footprint, and to benchmark those signals against industry patterns.

Between the lines: - Resolver is positioning the product around a regulatory pain point: pharma teams need wider web visibility, but must do it in a compliant and audit-ready way. - The launch also reflects growing pressure on pharma brands to spot misinformation and safety signals in community-based channels that traditional monitoring tools often miss. - By combining automated detection with human review, Resolver is aiming to make risk monitoring usable for both communications and pharmacovigilance teams.

What’s next: - Pharma organizations can request a Pharma Risk Briefing to evaluate the service. - Resolver says teams can use the offering to benchmark what they are seeing against broader industry trends. - The company is pushing the service as a way to support compliance and faster response across the wider web.

The bottom line: - Resolver is betting that pharma brands will pay for a managed, compliance-focused way to monitor risk beyond social media and onto the wider web.